News
SANA
8.72
+2.59%
0.22
Weekly Report: what happened at SANA last week (0415-0419)?
Weekly Report · 4d ago
Sana Biotechnology EVP and President of R&D Resigns
TipRanks · 04/18 21:12
Weekly Report: what happened at SANA last week (0408-0412)?
Weekly Report · 04/15 09:11
Weekly Report: what happened at SANA last week (0401-0405)?
Weekly Report · 04/08 09:11
Weekly Report: what happened at SANA last week (0325-0329)?
Weekly Report · 04/01 09:11
Weekly Report: what happened at SANA last week (0318-0322)?
Weekly Report · 03/25 09:11
Weekly Report: what happened at SANA last week (0311-0315)?
Weekly Report · 03/18 09:11
Sana Biotechnology: Now In Overbought Territory
Shares of Sana Biotechnology, Inc. Are up over 30% since pricing a secondary offering in February 2024. The company is focused on developing engineered cells to treat diseases. Sana has three clinical programs in Phase 1 trials, with promising results in the treatment of B-cell cancer and type I diabetes. Sana uses a hypoimmune technology platform to create cells that evade immune detection.
Seeking Alpha · 03/17 11:35
Institutional investors may overlook Sana Biotechnology, Inc.'s (NASDAQ:SANA) recent US$119m market cap drop as long-term gains remain positive
Institutional investors hold 46% of Sana Biotechnology, Inc. (NASDAQ:SANA) The top 6% of the company's shares are held by the top 6 shareholders of the business. The company has a significant amount of institutional ownership of the stock. Institutions hold a substantial stake in Sana Biotech, Inc., with a value of US$206m. Most of the shares in the company are owned by institutions, but there are other groups of shareholders as well. Sana biotechnology is showing 6 warning signs in our analysis of its share price.
Simply Wall St · 03/13 10:22
Have Sana Biotechnology Insiders Been Selling Stock?
Independent Director Patrick Yang sold US$236k worth of shares in Sana Biotechnology, Inc. (NASDAQ:SANA) recently. The sale is the biggest insider sale in the last year at a price of US$9.45 each. The company boasts high insider ownership, but we're a little cautious. Sana Biotech insiders own 9.8% of the company, currently worth about US$206m. The insider sale of shares at around the current price makes us cautious about the company. Sana biotechnology has 6 warning signs we think you should check out.
Simply Wall St · 03/13 10:08
Weekly Report: what happened at SANA last week (0304-0308)?
Weekly Report · 03/11 09:11
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
Shares of Tesla, Inc. (NASDAQ:TSLA) fell 5.4% to $191.79 on Monday. The company reportedly saw a decline in February China sales. The Dow Jones index fell around 80 points in today's session. Other big U.S. Stocks recording losses include MMTec, Victoria's Secret and Spirit Airlines.
Benzinga · 03/04 15:40
Weekly Report: what happened at SANA last week (0226-0301)?
Weekly Report · 03/04 09:11
DXCM, CDW and VRM are among after hour movers
On the Move DXCM, CDW and VRM are among after hour movers. Energem (ENCP) and CalAmp (CAMP) are among the Gainers. Sana Biotechnology (SANA) and Vroom (VRM) are the losers.
Seeking Alpha · 03/01 22:42
Sana Biotechnology files for mixed shelf offering
Sana Biotechnology files for mixed shelf offering without disclosing the amount. Sana Biotechnology, Inc. (SANA) Stock. Sana filed a prospectus related to a proposed mixed shelf offer. The company is a subsidiary of Saudi Arabia-based Sana Pharmaceuticals Ltd.
Seeking Alpha · 03/01 21:22
Sana Biotechnology Inc Files For Mixed Shelf; Size Not Disclosed
Benzinga · 03/01 21:15
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Zscaler, Inc. Shares fell 10.1% to $217.43 following second-quarter results. The company posted better-than-expected earnings and sales results for its second quarter on Thursday. BioVie Inc. And Dell Technologies were among the stocks moving in today's mid-day session.
Benzinga · 03/01 18:19
Sana Biotechnology Price Target Raised to $15.00/Share From $8.00 by JMP Securities
Dow Jones · 03/01 17:09
Sana Biotechnology Is Maintained at Market Outperform by JMP Securities
Dow Jones · 03/01 17:09
JMP Securities Maintains Market Outperform on Sana Biotechnology, Raises Price Target to $15
Benzinga · 03/01 16:59
More
Webull provides a variety of real-time SANA stock news. You can receive the latest news about Sana Biotechnology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SANA
Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.